Florida's Kratom Landscape: Navigating Evolving Regulations as 7-OH Emergency Ban Nears Expiration

Florida's Kratom Landscape: Navigating Evolving Regulations as 7-OH Emergency Ban Nears Expiration

Tallahassee, FL – As kratom use reportedly increases across Florida, merchants and consumers are closely watching the state's evolving regulatory environment, particularly with the impending expiration of an emergency ban on the synthetic kratom-derived compound 7-hydroxymitragynine (7-OH) on June 30, 2026. This situation highlights the critical importance of understanding current and developing compliance requirements for all involved in the kratom industry.

What Happened: Clarifying the "Ban"

Recent reports suggest a "statewide ban" on kratom is expiring, leading to increased use. However, it's crucial to clarify that a comprehensive statewide ban on kratom itself has not been in effect. Instead, Florida has been operating under the Florida Kratom Consumer Protection Act (KCPA), which became law in June 2023 and took effect on July 1, 2023. This act regulates the sale of kratom, prohibiting sales to individuals under 21 years of age and establishing definitions for kratom products.

The "ban" referred to in recent news likely pertains to an emergency rule issued by the Florida Attorney General in August 2025, which outlawed the sale of 7-OH concentrates above 0.04%. This emergency rule, aimed at a synthetic opioid byproduct of kratom considered highly addictive and significantly more potent than morphine, is indeed set to expire on June 30, 2026. Efforts to make this ban permanent failed during the 2026 legislative session.

Furthermore, the KCPA was significantly revised by legislation (HB 1489/SB 1734) effective July 1, 2025, which introduced stricter requirements for the distribution, sale, and manufacturing of kratom products.

Why It Matters to Kratom Merchants and Consumers

For consumers, the expiration of the 7-OH emergency ban creates uncertainty regarding the availability of this potent substance. While the primary kratom leaf remains regulated under the KCPA, the potential re-emergence of unregulated 7-OH products could pose significant health risks due to its addictive nature and high potency.

For merchants, the landscape is one of increasing regulation, not deregulation. The continued enforcement of the KCPA, reinforced by the 2025 revisions, means that operating in Florida requires strict adherence to state law. The reported increase in kratom use signals a growing market, but also amplified scrutiny from regulators. Merchants must be prepared for rigorous oversight, especially concerning product safety and labeling.

Compliance Implications

The Florida Department of Agriculture and Consumer Services (DACS) is tasked with administering and enforcing the KCPA. Key compliance implications for merchants include:

• Age Restrictions: Strictly prohibiting the sale of kratom products to individuals under 21 years of age.
• Product Definitions: Adhering to the state's definitions of "kratom product" and avoiding the sale of synthetic kratom products or those containing dangerous or harmful substances.
• Establishment Requirements: Kratom products may only be sold at establishments that have a food permit from DACS.
• Remote Sales: Specific requirements exist for mail, internet, and remote sales, including age verification and packaging statements.
• 7-OH Status: While the emergency ban on 7-OH expires, the DACS has issued new, detailed labeling requirements for 7-OH, indicating continued regulatory attention to this compound. Merchants should exercise extreme caution and seek legal counsel regarding 7-OH products.

What High-Risk Merchants Need to Know About COAs, Lab Testing, and Regulatory Compliance

High-risk kratom merchants operating in Florida must prioritize robust compliance measures, particularly regarding product quality and transparency. The revised KCPA mandates stringent requirements for Certificates of Analysis (COAs) and lab testing:

• Accredited Third-Party Labs: COAs must originate from an independent, third-party laboratory holding and maintaining ISO/IEC 17025 accreditation. Processors are prohibited from having any financial interest in the testing laboratory or its accrediting body.
• Comprehensive Testing Panel: The COA must verify that the kratom product has been tested for a range of substances, including:
  • Synthetic alkaloids and 7-hydroxymitragynine (7-OH).
  • Heavy metals (e.g., lead, arsenic, cadmium, mercury).
  • Mycotoxins.
  • Pesticides.
  • Potency (mitragynine and 7-hydroxymitragynine content).
  • Residual solvents.
  • Any other controlled substance or substance deemed necessary by DACS.
• COA Content and Retention: The COA must include the lot or batch identification number (matching the product label), date received, date of testing completion (within the last six months for registration), method of analysis, and the name and address of both the processor and the testing laboratory. Processors must retain COAs for at least one year after the product's expiration date.
• Labeling Requirements: Product labels must clearly identify the product by a unique batch or lot number that matches the COA, state the suggested use including serving size, list the amount of mitragynine and 7-hydroxymitragynine, provide the manufacturer/distributor name and address, and include an FDA disclaimer. Packaging must also be suitable for human consumption, minimize light exposure, mitigate high temperatures, be a single color (non-transparent, except for a child-friendly logo), and include an expiration date.
• Prohibition on Adulterants: Kratom products cannot contain controlled substances, psilocin, muscimol, ibotenic acid, muscarine, cannabinoids, or any other deleterious substances. Synthetic kratom products are explicitly prohibited.

As Florida's kratom market continues to evolve, strict adherence to these comprehensive regulations is not just a legal requirement but a business imperative for maintaining consumer trust and avoiding severe penalties.